These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31929349)

  • 41. Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy.
    Grassi P; Verzoni E; Ratta R; Mennitto A; de Braud F; Procopio G
    Drug Des Devel Ther; 2016; 10():2167-72. PubMed ID: 27462141
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma.
    Wedekind MF; Ranalli M; Shah N
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28417541
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.
    Wiecek W; Karcher H
    PLoS One; 2016; 11(6):e0155389. PubMed ID: 27271250
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
    Choueiri TK; Escudier B; Powles T; Mainwaring PN; Rini BI; Donskov F; Hammers H; Hutson TE; Lee JL; Peltola K; Roth BJ; Bjarnason GA; Géczi L; Keam B; Maroto P; Heng DY; Schmidinger M; Kantoff PW; Borgman-Hagey A; Hessel C; Scheffold C; Schwab GM; Tannir NM; Motzer RJ;
    N Engl J Med; 2015 Nov; 373(19):1814-23. PubMed ID: 26406150
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges.
    González-Larriba JL; Maroto P; Durán I; Lambea J; Flores L; Castellano D;
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):217-226. PubMed ID: 28105863
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma.
    Ratta R; Verzoni E; Mennitto A; Pantano F; Martinetti A; Raimondi A; Sepe P; Sottotetti E; Mennitto R; Morelli D; Santini D; de Braud FG; Procopio G
    Tumori; 2021 Dec; 107(6):542-549. PubMed ID: 33153416
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.
    Blanchet B; Xu-Vuilard A; Jouinot A; Puisset F; Combarel D; Huillard O; Le Louedec F; Thomas F; Teixeira M; Flippot R; Mourey L; Albiges L; Pudlarz T; Joly C; Tournigand C; Chauvin J; Puszkiel A; Chatelut E; Decleves X; Vidal M; Goldwasser F; Oudard S; Medioni J; Vano YA
    Br J Cancer; 2024 Apr; 130(6):961-969. PubMed ID: 38272963
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers.
    Richter I; Poprach A; Zemankova A; Buchler T; Bartos J; Samal V; Studentova H; Rozsypalova A; Dvorak J; Brom O; Melichar B
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Mar; 166(1):97-104. PubMed ID: 33252116
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21).
    Mennitto A; Zattarin E; Di Maio M; Bimbatti D; De Giorgi U; Buti S; Santini D; Casadei C; Sorarù M; Messina C; Mucciarini C; Di Lorenzo G; Roviello G; Buttigliero C; Stellato M; Sepe P; Claps M; Guadalupi V; Ottini A; Pignata S; De Braud FG; Verzoni E; Procopio G
    Expert Rev Anticancer Ther; 2022 Jan; 22(1):115-121. PubMed ID: 34738499
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
    Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
    Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
    Gill DM; Hahn AW; Hale P; Maughan BL
    Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cabozantinib for the treatment of renal cell carcinoma.
    Escudier B; Lougheed JC; Albiges L
    Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.
    Martini DJ; Evans ST; Liu Y; Shabto JM; Uner OE; Olsen TA; Brown JT; Russler GA; Yantorni L; Caulfield S; Goldman JM; Nazha B; Harris WB; Master VA; Kucuk O; Carthon BC; Bilen MA
    Clin Genitourin Cancer; 2022 Feb; 20(1):53-59. PubMed ID: 34922840
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
    Roviello G; Generali D
    Eur Urol; 2017 Dec; 72(6):1027-1028. PubMed ID: 28760645
    [No Abstract]   [Full Text] [Related]  

  • 55. Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.
    Tannir NM; Schwab G; Grünwald V
    Curr Oncol Rep; 2017 Feb; 19(2):14. PubMed ID: 28247252
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reversible Cabozantinib-Induced Cardiomyopathy.
    Alhussein M; Hotte SJ; Leong DP
    Can J Cardiol; 2019 Apr; 35(4):544.e1-544.e2. PubMed ID: 30935646
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cabozantinib improves clinical outcomes in renal cancer.
    Das M
    Lancet Oncol; 2017 Jan; 18(1):e2. PubMed ID: 27890466
    [No Abstract]   [Full Text] [Related]  

  • 58. A simple and rapid liquid chromatography-mass spectrometry method to assay cabozantinib in plasma: Application to therapeutic drug monitoring in patients with renal cell carcinoma.
    Ferrer F; Solas C; Giocanti M; Lacarelle B; Deville JL; Gravis G; Ciccolini J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Feb; 1138():121968. PubMed ID: 31931326
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer.
    Di Nunno V; Cimadamore A; Santoni M; Scarpelli M; Fiorentino M; Ciccarese C; Iacovelli R; Cheng L; Lopez-Beltran A; Massari F; Montironi R
    Future Oncol; 2018 Oct; 14(25):2559-2564. PubMed ID: 30141348
    [No Abstract]   [Full Text] [Related]  

  • 60. Cabozantinib-related pneumothorax in rapidly responding patients with renal cell carcinoma.
    Iacovelli R; Ciccarese C; Mosillo C; Tortora G
    Lancet Oncol; 2019 Feb; 20(2):e124. PubMed ID: 30723040
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.